Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
Horizon Pharma PLC (NASDAQ:HZNP) Stake Decreased by Amalgamated Bank
Get Analysts' Upgrades and Downgrades Daily
Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
Other institutional investors have also recently bought and sold shares of the company. Wells Fargo & Company MN boosted its position in Horizon Pharma PLC by 12.6% in the first quarter. Wells Fargo & Company MN now owns 498,787 shares of the biopharmaceutical company’s stock valued at $7,372,000 after buying an additional 55,678 shares in the last quarter. Deltec Asset Management LLC boosted its position in Horizon Pharma PLC by 34.4% in the first quarter. Deltec Asset Management LLC now owns 195,778 shares of the biopharmaceutical company’s stock valued at $2,894,000 after buying an additional 50,078 shares in the last quarter. First Mercantile Trust Co. boosted its position in Horizon Pharma PLC by 2.7% in the first quarter. First Mercantile Trust Co. now owns 11,770 shares of the biopharmaceutical company’s stock valued at $174,000 after buying an additional 310 shares in the last quarter. Profund Advisors LLC boosted its position in Horizon Pharma PLC by 0.8% in the first quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock valued at $200,000 after buying an additional 112 shares in the last quarter. Finally, First Manhattan Co. purchased a new position in Horizon Pharma PLC during the first quarter valued at approximately $295,000. 84.12% of the stock is currently owned by hedge funds and other institutional investors.
Horizon Pharma PLC (NASDAQ:HZNP) opened at 13.01 on Thursday. The company has a 50-day moving average of $11.64 and a 200-day moving average of $14.16. The stock’s market capitalization is $2.12 billion. Horizon Pharma PLC has a 1-year low of $9.45 and a 1-year high of $23.44.
Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by $0.04. Horizon Pharma PLC had a positive return on equity of 21.51% and a negative net margin of 21.26%. The business had revenue of $220.90 million during the quarter, compared to the consensus estimate of $248.71 million. During the same quarter in the previous year, the business posted $0.34 earnings per share. The firm’s revenue was up 7.9% on a year-over-year basis. Analysts anticipate that Horizon Pharma PLC will post $0.84 earnings per share for the current fiscal year.
Horizon Pharma PLC declared that its board has authorized a stock buyback program on Monday, May 8th that allows the company to repurchase 1,000% of outstanding shares. This repurchase authorization allows the biopharmaceutical company to purchase shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: “[[title]]” was reported by [[site]] and is owned by of [[site]]. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at [[permalink]].
Several research firms have commented on HZNP. Jefferies Group LLC set a $26.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Wednesday, April 12th. Piper Jaffray Companies dropped their target price on shares of Horizon Pharma PLC from $32.00 to $30.00 and set an “overweight” rating on the stock in a research report on Friday, March 24th. BMO Capital Markets reissued a “buy” rating and set a $24.00 target price on shares of Horizon Pharma PLC in a research report on Wednesday, March 29th. Zacks Investment Research raised shares of Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Finally, BidaskClub raised shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Four analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $20.43.
In other Horizon Pharma PLC news, Director Michael G. Grey purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, May 10th. The shares were acquired at an average cost of $9.48 per share, for a total transaction of $94,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.20% of the stock is currently owned by company insiders.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).